NNVC

NanoViricides, Inc.

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

NanoViricides, Inc. (NNVC) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.9
EV / EBITDA -4.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -2.2%
Price Return 12M -15.1%
Catalyst Signal 0.00
Market Cap $34.5M
TTM Revenue N/A
Price / Sales N/A
ROE -101.5%

Historical Factor Score Progression

Held C for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) D+ (1.8) D (1.5) C+ (2.5) C+ (2.6) C (2.2)
2026-11-06 C+ (2.5) D+ (1.8) D (1.5) C+ (2.8) C+ (2.7) C (2.2)
2026-10-30 C+ (2.5) D+ (1.8) D+ (1.5) C+ (2.7) C+ (2.7) C (2.2)
2026-10-23 C+ (2.5) D+ (1.7) D (1.5) C+ (2.8) C+ (2.6) C (2.2)
2026-10-16 C+ (2.5) D+ (1.7) D (1.5) C (2.2) C+ (2.6) C- (2.1)
Page 1 of 3